Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04180371 · ClinicalTrials.gov registry record · Phase 1
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by BicycleTx Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT04180371 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is active but no longer recruiting, run by BicycleTx Limited. The registered enrollment target is 288 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04180371, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by BicycleTx Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BT5528
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Antwerp University Hospital (UZA) - Edegem
- Universitair Ziekenhuis Gent (UZ) - Ghent
- Gachon University Gil Medical Center - Incheon
- Severance Hospital, Yonsei University Health System - Seoul
- Institut Catala d'Oncologia - L'Hospitalet - Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
California
- California Cancer Associates for Research and Excellence, Inc. - Encinitas
- University of California - Irvine Medical Center - Orange
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Florida Cancer Specialists - Sarasota
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Oklahoma
- Stephenson Cancer Center (Oklahoma University) - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04180371
The ClinicalTrials.gov registry entry for NCT04180371 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The listed sponsor is BicycleTx Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04180371 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04180371 about?
NCT04180371 is a clinical study titled "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression". This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participant...
What is the current status of trial NCT04180371?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 288 participants. The study started on 2019-11-07. Estimated completion is 2027-07-31.
What conditions does trial NCT04180371 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Urothelial Cancer.
What interventions are being tested in trial NCT04180371?
The interventions under investigation include: Nivolumab (DRUG), BT5528 (DRUG).
Who is sponsoring clinical trial NCT04180371?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04180371 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.